{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:25:12Z","timestamp":1789597512234,"version":"build-2803163510"},"reference-count":122,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Med Rep"],"DOI":"10.3892\/mmr.2025.13615","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T04:46:16Z","timestamp":1751949976000},"page":"1-11","source":"Crossref","is-referenced-by-count":5,"title":["Blocking the IL\u20116 pathway to treat immune checkpoint inhibitor\u2011induced inflammatory arthritis (Review)"],"prefix":"10.3892","volume":"32","author":[{"given":"Liwen","family":"Zhao","sequence":"first","affiliation":[{"name":"Institute of Pain Medicine and Special Environmental Medicine, Co\u2011innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu 226019, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuting","family":"Feng","sequence":"additional","affiliation":[{"name":"Institute of Pain Medicine and Special Environmental Medicine, Co\u2011innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu 226019, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Jing","family":"Gao","sequence":"additional","affiliation":[{"name":"Institute of Pain Medicine and Special Environmental Medicine, Co\u2011innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu 226019, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzhen","family":"He","sequence":"additional","affiliation":[{"name":"Institute of Pain Medicine and Special Environmental Medicine, Co\u2011innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu 226019, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"key20250725114638_b1-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.gendis.2018.10.003","article-title":"2018 nobel prize in medicine awarded to cancer immunotherapy: Immune checkpoint blockade-A personal account","volume":"5","author":"Zang","year":"2018","journal-title":"Genes Dis"},{"key":"key20250725114638_b2-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/cai2.34","article-title":"Deaths and adverse events from adjuvant therapy with immune checkpoint inhibitors in solid malignant tumors: A systematic review and network meta-analysis","volume":"1","author":"Xie","year":"2022","journal-title":"Cancer Innov"},{"key":"key20250725114638_b3-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and Anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol"},{"key":"key20250725114638_b4-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1002\/cai2.155","article-title":"Combination therapy using low-dose anlotinib and immune checkpoint inhibitors for extensive-stage small cell lung cancer","volume":"3","author":"Li","year":"2024","journal-title":"Cancer Innov"},{"key":"key20250725114638_b5-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/cai2.23","article-title":"Opportunities and challenges of immune checkpoint inhibitors for extensive-stage small-cell lung cancer","volume":"1","author":"Zhao","year":"2022","journal-title":"Cancer Innov"},{"key":"key20250725114638_b6-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/cai2.75","article-title":"PD-1\/L1 inhibitors can improve but not replace chemotherapy for advanced urothelial carcinoma: A systematic review and network meta-analysis","volume":"2","author":"Mao","year":"2023","journal-title":"Cancer Innov"},{"key":"key20250725114638_b7-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","article-title":"CD28 and CTLA-4 coreceptor expression and signal transduction","volume":"229","author":"Rudd","year":"2009","journal-title":"Immunol Rev"},{"key":"key20250725114638_b8-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: A moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"key20250725114638_b9-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"513","DOI":"10.14348\/molcells.2022.2056","article-title":"Current understanding of cytotoxic T lymphocyte antigen-4 (CTLA-4) signaling in T-cell biology and disease therapy","volume":"45","author":"Kim","year":"2022","journal-title":"Mol Cells"},{"key":"key20250725114638_b10-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41419-023-06391-x","article-title":"Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy","volume":"15","author":"Babamohamadi","year":"2024","journal-title":"Cell Death Dis"},{"key":"key20250725114638_b11-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J Clin Oncol"},{"key":"key20250725114638_b12-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/CJI.0b013e31829fb7a2","article-title":"Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer","volume":"36","author":"Le","year":"2013","journal-title":"J Immunother"},{"key":"key20250725114638_b13-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"key20250725114638_b14-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"100177","DOI":"10.1016\/j.clinsp.2023.100177","article-title":"Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy","volume":"78","author":"Gutic","year":"2023","journal-title":"Clinics (Sao Paulo)"},{"key":"key20250725114638_b15-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/cai2.70","article-title":"A real-world study of immune checkpoint inhibitors in advanced triple-negative breast cancer","volume":"2","author":"Zhang","year":"2023","journal-title":"Cancer Innov"},{"key":"key20250725114638_b16-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/cai2.39","article-title":"PD-L1 blockade by immune checkpoint inhibitors impairs sensitivity to osimertinib in EGFR-mutant non-small cell lung cancer cells","volume":"1","author":"Sun","year":"2022","journal-title":"Cancer Innov"},{"key":"key20250725114638_b17-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"964442","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"key20250725114638_b18-mmr-32-3-13615","first-page":"727","article-title":"PD-1\/PD-L1 pathway: Current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"key20250725114638_b19-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","article-title":"Roles of PD-1\/PD-L1 pathway: Signaling, cancer, and beyond","volume":"1248","author":"Ai","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"key20250725114638_b20-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: A common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"key20250725114638_b21-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s10147-016-0958-0","article-title":"Basics of PD-1 in self-tolerance, infection, and cancer immunity","volume":"21","author":"Chikuma","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"key20250725114638_b22-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: Current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"key20250725114638_b23-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/iju.15378","article-title":"Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer","volume":"31","author":"De Velasco","year":"2024","journal-title":"Int J Urol"},{"key":"key20250725114638_b24-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1002\/cai2.163","article-title":"Predictive value of neutrophil-to-lymphocyte ratio for immune checkpoint inhibitor-related myocarditis among patients treated for non-small-cell lung cancer","volume":"4","author":"Xue","year":"2025","journal-title":"Cancer Innov"},{"key":"key20250725114638_b25-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"key20250725114638_b26-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1136\/annrheumdis-2017-eular.3875","article-title":"THU0562 Inflammatory joint disease triggered by immune checkpoint inhibitors","volume":"76","author":"Tucker","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key20250725114638_b27-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s11886-021-01530-2","article-title":"Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors","volume":"23","author":"Lee","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"key20250725114638_b28-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (irAEs): Diagnosis, management, and clinical Pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"key20250725114638_b29-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"105457","DOI":"10.1016\/j.jbspin.2022.105457","article-title":"Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer","volume":"90","author":"Melia","year":"2023","journal-title":"Joint Bone Spine"},{"key":"key20250725114638_b30-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"e14151","DOI":"10.1200\/JCO.2019.37.15_suppl.e14151","article-title":"Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI)","volume":"37","author":"Thapa","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20250725114638_b31-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/BOR.0000000000000701","article-title":"Treatment of immune checkpoint inhibitor-induced inflammatory arthritis","volume":"32","author":"Jeurling","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"key20250725114638_b32-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"key20250725114638_b33-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.2147\/JIR.S282600","article-title":"Monitoring and management of the patient with immune checkpoint inhibitor-induced inflammatory arthritis: Current perspectives","volume":"15","author":"Chan","year":"2022","journal-title":"J Inflamm Res"},{"key":"key20250725114638_b34-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"e000412","DOI":"10.1136\/rmdopen-2016-000412","article-title":"Rheumatic immune-related adverse events of checkpoint therapy for cancer: Case series of a new nosological entity","volume":"3","author":"Calabrese","year":"2017","journal-title":"RMD Open"},{"key":"key20250725114638_b35-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key20250725114638_b36-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","article-title":"Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: A case series","volume":"76","author":"Kim","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key20250725114638_b37-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"e28428","DOI":"10.1097\/MD.0000000000028428","article-title":"Immune checkpoint inhibitor-induced refractory polyarthritis rapidly improved by sarilumab and monitoring with joint ultrasonography: A case report","volume":"101","author":"Abe","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"key20250725114638_b38-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"3833","DOI":"10.1172\/JCI32567","article-title":"TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice","volume":"117","author":"Calzascia","year":"2007","journal-title":"J Clin Invest"},{"key":"key20250725114638_b39-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.smim.2014.01.007","article-title":"The IL-6 feed-forward loop: A driver of tumorigenesis","volume":"26","author":"Chang","year":"2014","journal-title":"Semin Immunol"},{"key":"key20250725114638_b40-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-09-0287","article-title":"Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma","volume":"15","author":"Shinriki","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20250725114638_b41-mmr-32-3-13615","article-title":"Common terminology criteria for adverse events (CTCAE) version 5.0","author":"U.S. Department of Health and Human Services"},{"key":"key20250725114638_b42-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/acr2.1026","article-title":"Sonographic findings in inflammatory arthritis secondary to immune checkpoint inhibition: A case series","volume":"1","author":"Albayda","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"key20250725114638_b43-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/acr.23467","article-title":"Arthritis after cancer immunotherapy: Symptom duration and treatment response","volume":"71","author":"Smith","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"key20250725114638_b44-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"key20250725114638_b45-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: A single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"key20250725114638_b46-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00262-017-2069-9","article-title":"Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies","volume":"67","author":"Buder-Bakhaya","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"key20250725114638_b47-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun Rev"},{"key":"key20250725114638_b48-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects","volume":"68","author":"Huscher","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key20250725114638_b49-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"e1249559","DOI":"10.1080\/2162402X.2016.1249559","article-title":"Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab","volume":"5","author":"Damuzzo","year":"2016","journal-title":"Oncoimmunology"},{"key":"key20250725114638_b50-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/j.clgc.2021.10.005","article-title":"Predictive impact of early changes in serum C-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma","volume":"20","author":"Tachibana","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"key20250725114638_b51-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/1759-7714.14248","article-title":"Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy","volume":"13","author":"Shi","year":"2022","journal-title":"Thorac Cancer"},{"key":"key20250725114638_b52-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S0161-5890(02)00210-9","article-title":"The two faces of IL-6 on Th1\/Th2 differentiation","volume":"39","author":"Diehl","year":"2002","journal-title":"Mol Immunol"},{"key":"key20250725114638_b53-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"100901","DOI":"10.1016\/j.xcrm.2022.100901","article-title":"Illuminating the mechanism of IL-6-mediated immunotherapy resistance","volume":"4","author":"Vilgelm","year":"2023","journal-title":"Cell Rep Med"},{"key":"key20250725114638_b54-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1158\/0008-5472.CAN-18-0118","article-title":"Combined blockade of IL6 and PD-1\/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment","volume":"78","author":"Tsukamoto","year":"2018","journal-title":"Cancer Res"},{"key":"key20250725114638_b55-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood.V74.1.1.1","article-title":"The biology of interleukin-6","volume":"74","author":"Kishimoto","year":"1989","journal-title":"Blood"},{"key":"key20250725114638_b56-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/324073a0","article-title":"Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin","volume":"324","author":"Hirano","year":"1986","journal-title":"Nature"},{"key":"key20250725114638_b57-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0022","article-title":"The biology and medical implications of interleukin-6","volume":"2","author":"Tanaka","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"key20250725114638_b58-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"key20250725114638_b59-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int Immunol"},{"key":"key20250725114638_b60-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.clim.2008.08.018","article-title":"The effects of IL-6 on CD4 T cell responses","volume":"130","author":"Dienz","year":"2009","journal-title":"Clin Immunol"},{"key":"key20250725114638_b61-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur J Immunol"},{"key":"key20250725114638_b62-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1146\/annurev-pharmtox-010611-134715","article-title":"Therapeutic targeting of the interleukin-6 receptor","volume":"52","author":"Tanaka","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"key20250725114638_b63-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1167\/iovs.10-6272","article-title":"Blockade of interleukin-6 signaling suppresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis","volume":"52","author":"Haruta","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20250725114638_b64-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1084\/jem.20120994","article-title":"The origins, function, and regulation of T follicular helper cells","volume":"209","author":"Ma","year":"2012","journal-title":"J Exp Med"},{"key":"key20250725114638_b65-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"41411","DOI":"10.1038\/srep41411","article-title":"Combination of IL-6 and sIL-6R differentially regulate varying levels of RANKL-induced osteoclastogenesis through NF-\u03baB, ERK and JNK signaling pathways","volume":"7","author":"Feng","year":"2017","journal-title":"Sci Rep"},{"key":"key20250725114638_b66-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2776(08)60532-5","article-title":"Interleukin-6 in biology and medicine","volume":"54","author":"Akira","year":"1993","journal-title":"Adv Immunol"},{"key":"key20250725114638_b67-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.26058.1","article-title":"Interleukin-6 signalling in health and disease","volume":"9","author":"Rose-John","year":"2020","journal-title":"F1000Res"},{"key":"key20250725114638_b68-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2022.04.001","article-title":"IL-6 and its role in IgA nephropathy development","volume":"66","author":"Groza","year":"2022","journal-title":"Cytokine Growth Factor Rev"},{"key":"key20250725114638_b69-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol"},{"key":"key20250725114638_b70-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.3390\/ijms23042019","article-title":"Classical signaling and trans-signaling pathways stimulated by megalobrama amblycephala IL-6 and IL-6R","volume":"23","author":"Wang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"key20250725114638_b71-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"688314","DOI":"10.3389\/fcell.2021.688314","article-title":"Endosomes as signaling platforms for IL-6 family cytokine receptors","volume":"9","author":"Schmidt-Arras","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"key20250725114638_b72-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.7150\/ijbs.4989","article-title":"IL-6 trans-signaling via the soluble IL-6 receptor: Importance for the pro-inflammatory activities of IL-6","volume":"8","author":"Rose-John","year":"2012","journal-title":"Int J Biol Sci"},{"key":"key20250725114638_b73-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41540-023-00308-2","article-title":"Experiment-based computational model predicts that IL-6 classic and trans-signaling exhibit similar potency in inducing downstream signaling in endothelial cells","volume":"9","author":"Song","year":"2023","journal-title":"NPJ Syst Biol Appl"},{"key":"key20250725114638_b74-mmr-32-3-13615","first-page":"82","article-title":"Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients","volume":"48","author":"Koz\u0142owski","year":"2003","journal-title":"Rocz Akad Med Bialymst"},{"key":"key20250725114638_b75-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/cam4.174","article-title":"Association between adjuvant regional radiotherapy and cognitive function in breast cancer patients treated with conservation therapy","volume":"3","author":"Shibayama","year":"2014","journal-title":"Cancer Med"},{"key":"key20250725114638_b76-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1006\/bbrc.1999.0515","article-title":"Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells","volume":"257","author":"Mori","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"key20250725114638_b77-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1038\/sj.onc.1203707","article-title":"Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells","volume":"19","author":"Klausen","year":"2000","journal-title":"Oncogene"},{"key":"key20250725114638_b78-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jss.2007.04.022","article-title":"Interleukin-6 mediates G(0)\/G(1) growth arrest in hepatocellular carcinoma through a STAT 3-dependent pathway","volume":"147","author":"Moran","year":"2008","journal-title":"J Surg Res"},{"key":"key20250725114638_b79-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/sj.onc.1202382","article-title":"Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1\/CIP1 is lost during progression of human malignant melanoma","volume":"18","author":"Fl\u00f8renes","year":"1999","journal-title":"Oncogene"},{"key":"key20250725114638_b80-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1038\/sj.onc.1202708","article-title":"Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27\/Kip1","volume":"18","author":"Kortylewski","year":"1999","journal-title":"Oncogene"},{"key":"key20250725114638_b81-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.biopha.2018.09.177","article-title":"The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer","volume":"108","author":"Masjedi","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"key20250725114638_b82-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"61107","DOI":"10.18632\/oncotarget.11243","article-title":"Interleukin-6 increases matrix metalloproteinase-14 (MMP-14) levels via down-regulation of p53 to drive cancer progression","volume":"7","author":"Cathcart","year":"2016","journal-title":"Oncotarget"},{"key":"key20250725114638_b83-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3390\/ph17010127","article-title":"Tocilizumab exerts anti-tumor effects on colorectal carcinoma cell xenografts corresponding to expression levels of interleukin-6 receptor","volume":"17","author":"Chung","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"key20250725114638_b84-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.3889\/oamjms.2019.589","article-title":"IL-6 activities in the tumour microenvironment. Part 1","volume":"7","author":"Chonov","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"key":"key20250725114638_b85-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.3389\/fimmu.2019.02638","article-title":"Activation of the IL-4\/STAT6 signaling pathway promotes lung cancer progression by increasing M2 myeloid cells","volume":"10","author":"Fu","year":"2019","journal-title":"Front Immunol"},{"key":"key20250725114638_b86-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"1023177","DOI":"10.3389\/fonc.2022.1023177","article-title":"The role of IL-6\/JAK2\/STAT3 signaling pathway in cancers","volume":"12","author":"Huang","year":"2022","journal-title":"Front Oncol"},{"key":"key20250725114638_b87-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"760971","DOI":"10.3389\/fonc.2021.760971","article-title":"IL-6\/STAT3 is a promising therapeutic target for hepatocellular carcinoma","volume":"11","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"key":"key20250725114638_b88-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"e102436","DOI":"10.1371\/journal.pone.0102436","article-title":"Tocilizumab, a proposed therapy for the cachexia of interleukin6-expressing lung cancer","volume":"9","author":"Ando","year":"2014","journal-title":"PLoS One"},{"key":"key20250725114638_b89-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1517\/14712598.2011.627850","article-title":"A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer","volume":"11","author":"Bayliss","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"key20250725114638_b90-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"e006814","DOI":"10.1136\/jitc-2023-006814","article-title":"Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events","volume":"11","author":"Fa'ak","year":"2023","journal-title":"J Immunother Cancer"},{"key":"key20250725114638_b91-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","article-title":"Targeting interleukin-6 in inflammatory autoimmune diseases and cancers","volume":"141","author":"Yao","year":"2014","journal-title":"Pharmacol Ther"},{"key":"key20250725114638_b92-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/bjc.2013.748","article-title":"Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction","volume":"110","author":"Nagasaki","year":"2014","journal-title":"Br J Cancer"},{"key":"key20250725114638_b93-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/j.ejca.2012.11.038","article-title":"Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression","volume":"49","author":"Oguro","year":"2013","journal-title":"Eur J Cancer"},{"key":"key20250725114638_b94-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/cdd.2017.162","article-title":"IL6 blockade potentiates the anti-tumor effects of \u03b3-secretase inhibitors in Notch3-expressing breast cancer","volume":"25","author":"Wang","year":"2018","journal-title":"Cell Death Differ"},{"key":"key20250725114638_b95-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"e005111","DOI":"10.1136\/jitc-2022-005111","article-title":"COLAR: Open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis","volume":"10","author":"Holmstroem","year":"2022","journal-title":"J Immunother Cancer"},{"key":"key20250725114638_b96-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/art.40745","article-title":"Rheumatic syndromes associated with immune checkpoint inhibitors: A single-center cohort of sixty-one patients","volume":"71","author":"Richter","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"key20250725114638_b97-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"key20250725114638_b98-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"e14243","DOI":"10.1200\/JCO.2019.37.15_suppl.e14243","article-title":"A phase II study of cryoablation (cryo) of an enlarging tumor in patients (pts) with advanced lung cancer or melanoma receiving post-progression immune checkpoint inhibition (ICI)","volume":"37","author":"Mooradian","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20250725114638_b99-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"1759720\u00d7211006963","DOI":"10.1177\/1759720X211006963","article-title":"Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: A single-centre analysis","volume":"13","author":"Verspohl","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"key20250725114638_b100-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"e003795","DOI":"10.1136\/rmdopen-2023-003795","article-title":"Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: A multicentre observational study","volume":"9","author":"Ladouceur","year":"2023","journal-title":"RMD Open"},{"key":"key20250725114638_b101-mmr-32-3-13615","first-page":"573","article-title":"Tocilizumab in a patient with newly diagnosed rheumatoid arthritis secondary to checkpoint inhibitor therapy","volume":"38","author":"Pirker","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"key20250725114638_b102-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.semarthrit.2018.10.012","article-title":"Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience","volume":"48","author":"Mooradian","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"key20250725114638_b103-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1136\/annrheumdis-2022-eular.3614","article-title":"POS1356 treatment of immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica","volume":"81","author":"Liapi","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"key20250725114638_b104-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1182\/bloodadvances.2019000925","article-title":"Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes","volume":"3","author":"Saygin","year":"2019","journal-title":"Blood Adv"},{"key":"key20250725114638_b105-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: From bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"key20250725114638_b106-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"114027","DOI":"10.1016\/j.ejca.2024.114027","article-title":"Novel use of abatacept and ruxolitinib as salvage therapy in steroid-refractory immune checkpoint blockade-induced myocarditis with myasthenia and myositis overlap syndrome","volume":"202","author":"Byer","year":"2024","journal-title":"Eur J Cancer"},{"key":"key20250725114638_b107-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.chembiol.2006.09.018","article-title":"Stattic: A small-molecule inhibitor of STAT3 activation and dimerization","volume":"13","author":"Schust","year":"2006","journal-title":"Chem Biol"},{"key":"key20250725114638_b108-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/13543780802565791","article-title":"Targeting STAT3 in cancer: How successful are we?","volume":"18","author":"Yue","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"key20250725114638_b109-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.3389\/fimmu.2019.02298","article-title":"The diverse function of PD-1\/PD-l pathway beyond cancer","volume":"10","author":"Qin","year":"2019","journal-title":"Front Immunol"},{"key":"key20250725114638_b110-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1002\/art.27500","article-title":"The programmed death 1\/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis","volume":"62","author":"Raptopoulou","year":"2010","journal-title":"Arthritis Rheum"},{"key":"key20250725114638_b111-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/art.20966","article-title":"A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese","volume":"52","author":"Kong","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key20250725114638_b112-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/cei.12949","article-title":"Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1","volume":"188","author":"Bommarito","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"key20250725114638_b113-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"100878","DOI":"10.1016\/j.xcrm.2022.100878","article-title":"CD8+T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy","volume":"4","author":"Huseni","year":"2023","journal-title":"Cell Rep Med"},{"key":"key20250725114638_b114-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"906824","DOI":"10.3389\/fonc.2022.906824","article-title":"Increased circulating levels of CRP and IL-6 and decreased frequencies of T and B lymphocyte subsets are associated with immune-related adverse events during combination therapy with PD-1 inhibitors for liver cancer","volume":"12","author":"Yu","year":"2022","journal-title":"Front Oncol"},{"key":"key20250725114638_b115-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1200\/JCO.2012.45.5568","article-title":"Targeting oncogenic drivers and the immune system in melanoma","volume":"31","author":"McArthur","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20250725114638_b116-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"key20250725114638_b117-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"6762","DOI":"10.1074\/jbc.RA117.001163","article-title":"The balance of interleukin (IL)-6, IL-6\u00b7soluble IL-6 receptor (sIL-6R), and IL-6\u00b7sIL-6R\u00b7sgp130 complexes allows simultaneous classic and trans-signaling","volume":"293","author":"Baran","year":"2018","journal-title":"J Biol Chem"},{"key":"key20250725114638_b118-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"key20250725114638_b119-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell"},{"key":"key20250725114638_b120-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/OARRR.S17118","article-title":"Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis","volume":"3","author":"Mihara","year":"2011","journal-title":"Open Access Rheumatol"},{"key":"key20250725114638_b121-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"990794","DOI":"10.3389\/fimmu.2022.990794","article-title":"Metabolic requirements of Th17 cells and of B cells: Regulation and defects in health and in inflammatory diseases","volume":"13","author":"Bystrom","year":"2022","journal-title":"Front Immunol"},{"key":"key20250725114638_b122-mmr-32-3-13615","doi-asserted-by":"publisher","first-page":"750753","DOI":"10.3389\/fimmu.2021.750753","article-title":"B cells in rheumatoid arthritis: Pathogenic mechanisms and treatment prospects","volume":"12","author":"Wu","year":"2021","journal-title":"Front Immunol"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T08:46:44Z","timestamp":1753433204000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mmr.2025.13615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":122,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,7,8]]}},"URL":"https:\/\/doi.org\/10.3892\/mmr.2025.13615","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]}}}